STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Steris (STE) Hits Fresh High: Is There Still Room to Run?

Steris PLC STE, +1.18% said Tuesday it has agreed to acquire Key Surgical, a portfolio company of Water Street Healthcare Partners LLC for $850 million. Dublin, Ireland-based Steris expects the deal to qualify for a tax benefit that will reduce the purchase price to $810 million.

Steris PLC to acquire Key Surgical for $850 million

DUBLIN, IRELAND, Oct. 06, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase Key Surgical, a portfolio company of Water Street Healthcare Partners, LLC, through a U.S. subsidiary for $850 million.  STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill.  Adjusting for the present value of the anticipated tax benefit, the purchase price is effectively reduced to approximately $810 million.  Key Surgical, founded in 1988, is a leading global provider of consumable products serving hospitals and surgical facilities.  Annual revenue for Key Surgical in calendar 2020 is anticipated to be approximately $170 million, with adjusted EBIT of approximately $50 million.

STERIS Expands Healthcare Consumables Offering with Acquisition of Key Surgical for approximately $850 million

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Up 0.5% Since Last Earnings Report: Can It Continue?

Badger Meter

Dover

Ritchie Bros. Auctioneers

Scotts Miracle-Gro

5 Dividend Increases For The Week Of August 23rd With 1 Dividend King

STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

•          First quarter revenue declines low-single digits due to reduction in deferrable procedures  •          First quarter net income grows low-single digits driven by margin expansion  •          Board increases dividend for 15th consecutive year

STERIS Announces Financial Results for Fiscal 2021 First Quarter

DUBLIN, IRELAND, July  22, 2020  (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 first quarter financial results at 10:00 a.m. Eastern Time on Tuesday, August 4, 2020.  The conference call can be heard live over the Internet at  www.steris-ir.com  or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. 

STERIS to Host a Conference Call for Fiscal 2021 First Quarter Financial Results on August 4, 2020

As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.

STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes

Fortive

Steris and Fortive are on the rise, thanks in part to their medical devices used to decontaminate N95 or N95-equivalent respirators.

These 2 Stocks Are Cleaning Up Thanks To Medical Mask Sterilization. Are They Buys?

DUBLIN, IRELAND, May  26, 2020  (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has issued another Emergency Use Authorization (EUA) for respirator decontamination.  The EUA enables healthcare providers to decontaminate surgical N95 respirators by utilizing certain AMSCO Steam Sterilizers that have been upgraded with STERIS’s new “Decon” cycle. 

STERIS Announces Second On-site Decontamination Solution for Respiratory Masks

STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.

STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise

STERIS' (STE) CEO Walt Rosebrough on Q4 2020 Results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 4.46% and 4.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Q4 Earnings and Revenues Surpass Estimates

DUBLIN, IRELAND, May  13, 2020  (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020.  Revenue as reported for the quarter increased 7% to $823.0 million compared with $768.2 million in the fourth quarter of fiscal 2019, with growth across all segments. Constant currency organic revenue (see Non-GAAP Financial Measures) growth was 8% for the fourth quarter of fiscal 2020.

STERIS Announces Financial Results for Fiscal 2020 Fourth Quarter and Full Year

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DUBLIN, IRELAND, April  10, 2020  (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for respirator decontamination.  The EUA enables healthcare providers to decontaminate N95 Respirators on-site by utilizing certain STERIS V-PRO® Low Temperature Sterilization Systems.

STERIS Announces Decontamination Solution for Respiratory Masks

Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

Campbell Soup

Equinix

MarketAxess Holdings

Regeneron Pharmaceuticals

Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.

5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus

STERIS (STE) continues to register stellar organic growth across all four operating segments.

STERIS' (STE) Organic Growth Robust Amid Bottom-Line Hurdles

Enova Int.

Medtronic

Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.

3 Top Stocks to Buy for Earnings Acceleration

Steris shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 82.
The post Steris Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

Steris Meets 80-Plus Relative Strength Rating Benchmark

Steris (STE) Down 6.9% Since Last Earnings Report: Can It Rebound?

STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

News for STERIS Stock (STE)